| Class | Parenteral anticoagulant |
|---|---|
| Chemistry |
Glycosaminoglycan |
| Routes of administration |
IV ands subcut |
| Absorption |
Minimal oral bioavailability (~ 1%) |
| Solubility |
pKa -2.6, excellent solubility in water |
| Distribution |
VOD=0.05L/kg, basically confined to the bloodstream. |
| Metabolism |
Small amount of dalteparin is metabolised into lower molecular weright framents, mainly in the liver |
| Elimination |
70% of dalteparin is eliminated via the kidneys. |
| Time course of action |
Half life is about 3-5 hours. |
| Target receptor |
Antithrombin III |
| Mechanism of action |
By binding to antithrombin III and causing the active site to undergo a conformational change, low molecular weight heparin increases its affinity for factor Xa (but not thrombin). The result is an increase in the activity of antithrombin on Factor Xa, which manifests in the form of the anticoagulant effect. |
| Clinical effects |
Anticoagulation is the only clinically apparent effect; no significant side effects apart from the possibility of HITS (which is much smaller than with UFH) |
| Literature reference |
Fragmin PI document |
| CICM details of understanding | Not specifically listed in the CICM syllabus |
| Mentioned around Deranged Physiology | |
| Related SAQs |